Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

Table 1

Genomic subtypes of GIST patients included in the meta-analysis.

Author (year)	Dosage	CBR (%)	Genotype (/)
			KIT	Exon 9	Exon 11	Exon 13	Exon 17	WT	PDGFRA
Heinrich et al. (2008) [7]	50 mg/day (4/2) or 37.5 mg/day CDD	42	27/64	11/19	15/44	1/1	NA	5/9	0/4
Chen et al. (2011) [15]		62	12/19	3/6	9/12	0/1	NA	0/1	1/1
Koh et al. (2011) [16]		78	10/12	1/1	9/11	NA	NA	2/3	2/3
Li et al. (2012) [17]		68	19/29	6/6	13/22	NA	0/1	6/8	NA
Rutkowski et al. (2012) [18]		62	46/67	13/15	33/52	NA	NA	7/10	2/12
Yoon et al. (2012) [19]		49	29/58	7/11	22/47	NA	NA	6/12	1/4
Reichardt et al. (2016) [20]		67	NA/196	37/42	95/143	NA/5	NA/6	NA/9	NA/18

4/2: 4-weeks-on, 2-weeks-off; CDD: continuous daily dose; NA: not available; CBR: clinical benefit rate; of patients with complete response (CR) + partial response (PR) + stable disease (SD) according to the Response Evaluation Criteria in Solid Tumors (RECIST); number of patients with genotype; WT: wild-type.